SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (846)11/21/1997 4:03:00 AM
From: Skywatcher  Respond to of 7041
 
Mention in Motley Fool Lunchtime
Impotency pill company Zonagen Inc. (Nasdaq:ZONA) fought claims by Asensio & Co. that late-stage trials of its pill were flawed, which helped the stock $3 1/8 to $31 5/8. A spokesman for the company said
Vasomax was properly tested and had proved effective and safe in four completed late-stage trials involving 1100 patients.



To: Skywatcher who wrote (846)11/21/1997 4:05:00 AM
From: Skywatcher  Respond to of 7041
 
Also on Motley today
More impotence-related news! Vivus, Inc. (Nasdaq:VVUS) , which makes pharmacological systems to help impotency, rose $2 1/16 to $24 15/16 after it announced that it was notified by the Food and Drug
Administration (FDA) that its original manufacturing facility is in compliance with the FDA's current Good
Manufacturing Practice requirements.
chris


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News